Pharma Amgen Netherlands is preparing to launch five new products next year, including their leading cardiovascular biotech product Repatha and recently announced the acquisition of the Dutch biotech Dezima. General manager Jasper van Grunsven explains the challenges of preparing for the upcoming year in the midst of structural changes to the…
Pharma Bert de Jong, General Manager Benelux at Genzyme, discusses the solutions Genzyme is offering to patients suffering from rare diseases and MS in the Benelux and how these treatments add value overall to society, as well as the company’s changing role in the Sanofi organization with the addition of the oncology and…
Pharma The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising pipeline of innovative products, her “positively opportunistic” attitude towards partnerships and international expansion, and the company’s overall strategy for differentiating…
Pharma Abbvie has taking a leading role in the Egyptian pharmaceutical industry by bringing their new all-oral hepatitis C treatment to Egypt, the country with the highest prevalence of the disease in the world, making the company a major stakeholder in the country’s highest priority healthcare issue. How would you assess…
Pharma Aurélien Chaufour reveals how Anjac Health and Beauty has developed with a focus on innovation and industrial know-how since its creation in 2008 and how he today has four companies that are experts in the fields of health, hygiene and beauty. Chaufour also reveals why there is long-term future for…
Pharma Théa’s Jean-Frederic Chibret reveals how as a company focused purely on ophthalmology, they have the expertise to focus on niche areas that big pharma companies neglect; how they are the third largest pharma ophthalmic company in Europe, and the only pan-European ophthalmic company to have its headquarters on the continent, and…
pharma Mr Martinez, President of Santen France, reveals how Santen’s decision to acquire the French pharmaceutical company Novagali in 2011, was based on its desire to project itself as an innovative ophthalmic player across the whole of Europe and why 2015 was a significant year for the group, receiving European marketing approval…
Pharma The president of HAS sheds light on the seemingly complex French healthcare system, explains HAS’ role within that context and provides an honest assessment of the system’s advantages and flaws. He also discusses the issues of maintaining the sustainability of the French healthcare budget and the importance of increasing European…
Pharma John Verhoeven, Partner and co-founder of Eagle Rock Life Sciences, a Dutch independent consultancy offering a broad range of services to both Dutch and international life sciences companies, explains how this fast-growing company helps clients of all sizes to reach new heights thanks to its experienced staff and fast, flexible service.…
Pharma Manfred Rüdiger (MR), Robbert Van Heekeren (RVH) and Jeroen Rovers (JR), respectively CEO, CFO and CMO of Kiadis Pharma, a Dutch biopharmaceutical company focused on cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders, discuss how the company’s recent IPO will allow them to move forward…
pharma Rikus Wolbers, Director at Novio Tech Campus, a key international incubator for R&D and manufacturing companies who are active at the interface of life sciences and high tech, and John Schalken, Program Director SMB Life Sciences, give an overview of the impressive developments in the Nijmegen area and the potential…
pharma Jan Smeitink, CEO of Khondrion, a young biotech company designing highly innovative solutions for people suffering from mitochondrial diseases, provides an overview of the latest developments regarding the company’s lead compound and explains how its talented team and strategic partnership with the Radboud University Medical Centre will help Khondrion to…
See our Cookie Privacy Policy Here